Browsing by Subject "Insulin-Like Growth Factor Binding Protein 3"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
Item Immunohistochemical staining of IGF-I, IGF-binding proteins-1 and -3, and transforming growth factor beta-3 in the umbilical cords of preeclamptic patients(2002) Inan S.; Vatansever S.; Kuscu N.K.; Laçin S.; Ozbilgin K.; Koyuncu F.Background. To detect the immunoreactivity of insulin-like growth factor-I, insulin-like growth factor-binding proteins-1 and -3 and transforming growth factor beta-3 in the umbilical cords of normal and preeclamptic patients. Methods. Umbilical cords were obtained from 15 normal and 15 preeclamptic patients. Immunoreactivities were determined using either indirect immunofluorescence or immunoperoxidase techniques on formalin-fixed, paraffin-embedded sections. Staining intensity was graded by a semiquantitative scoring method. The results were compared by Mann-Whitney U-test. Results. The umbilical cords were thinner and the vessels were hypoplastic in the preeclamptic group. Moderate staining intensity for insulin-like growth factor-I, insulin-like growth factor binding protein-1 and -3 and transforming growth factor-beta 3 was observed in normal patients. The preeclamptic group had mild and strong intensities for insulin-like growth factor-I and insulin-like growth factor binding protein-1, respectively, and intensity for insulin-like growth factor binding protein-3 did not change, but diffuse and increased intensity was observed for transforming growth factor-beta 3. Conclusion. Changes in the intensity of insulin-like growth factor-I and its major binding protein and the transformation of growth factor-beta 3 may play a role in the pathogenesis of preeclampsia by altering the structure and responsiveness of the umbilical cord.Item Serum level of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in acute coronary syndromes and relationship with prognosis; [Akut Koroner Sendromlarda ̇ Insl̈in Benzeri Büyüme Faktörü-I ve ̇ Insülin Benzeri Büyüme Faktörü Baǧlayici Protein-3 Düzeyleri ve Prognozla ̇ Ilişkisi](2004) Şekuri C.; Arslan Ö.; Ütük O.; Bayturan Ö.; Onur E.; Tezcan U.K.; Tavli T.Objective: The aim of the present study was to examine the levels of insulin-like growth factor (IGF-I) and binding protein-3 (IGFBP-3) in acute coronary syndrome (ACS) and their relationship with prognosis. Methods: Thirty patients with ACS (22 male, 8 female) were included in our study. Patient's population included 20 patients with ST elevation myocardial infarction (STEMI) and 10 with non-ST-elevation ACS. Death, re-infarction, revascularization and malignant arrhythmia were monitored during 3 months. Study group was compared with 20 healthy subjects (Controls). Blood samples were collected in the first 24 hours and at the end of third month. Serum IGF-I and IGFBP-3 levels were determined by radioimmunoassay method. Results: We found decreased level of IGF-I only in the STEMI group (105±84 ng/ml vs. 715±150 ng/ml, p<0.0001). There were no significant differences in IGFBP-3 levels between two groups. Serum IGF-I levels were significantly increased after 3rd month in the STEMI group (356±72 ng/ml vs. 105±84 ng/ml, p=0.025). There was no relationship between IGF-I, IGFBP-3 levels and cardiovascular events occurred during 90 days of follow-up. Conclusion: These data allows to suggest that significantly decreased level of IGF-I in STEMI group of ACSs can be used as a marker of myocardial necrosis. There was no relationship between IGF-I level and cardiovascular events occurred in 90 days, so this parameter can not be used as a negative prognostic factor.Item Changes in growth pattern, body composition and biochemical markers of growth after adenotonsillectomy in prepubertal children(2005) Ersoy B.; Yücetürk A.V.; Taneli F.; Ürk V.; Uyanik B.S.Objective: Adenotonsillar hypertrophy (ATH) is associated with growth interruption during childhood. The aim of this study was to determine the changes in growth, body composition and biochemical markers associated with growth following adenotonsillectomy (A&T) in prepubertal children. Study design: Twenty-eight children aged 3-10 years (mean age 73.90 ± 20.97 months) with ATH were followed up for 1 year after A&T. During the same period of time, 20 healthy children of similar ages (mean age 73.7 ± 18.2 months) were followed up too. Methods: Height, weight as well as insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) were measured during the preoperative period, 6 months and 1 year after surgery. Results: Height and weight of the patient group significantly increased during the first year after A&T (p < 0.01). Increase in height standard deviation score (SDS) during the first postoperative year reflected a true acceleration of growth (p = 0.04). Height and weight of patients were not significantly below those of their healthy peers at the preoperative measurement. Height velocity of the patients (p = 0.118), which was similar to that of their healthy peers in the first 6 months postoperatively, was significantly higher at the end of the second 6-month period after the operation (p = 0.048). IGF-1 levels of the patient group, which were significantly lower than those of the controls preoperatively (p < 0.001), increased to similar levels 1 year after the operation. IGFBP-3 levels of the patient group increased significantly after postoperative sixth month (p = 0.002). Conclusion: Although children with ATH do not have significant growth retardation, their growth rate is slower. Increase in weight and IGF-1 levels followed by the increase in height leads to an acceleration in growth rate after A&T. These results have led to the conclusion that either the levels or effect of growth hormone (GH) increase following A&T. © 2005 Elsevier Ireland Ltd. All rights reserved.Item Interactions of thyroid hormones; Insulin-like growth factor-1 (IGF-1), igf binding proteins, and nutritional anthropometric parameters in school children with goiter detected by palpation(2009) Ersoy B.; Gunes H.S.; Uyanik B.S.; Taneli F.; Gunay T.Aim: In the present study we evaluated anthropometric indices, serum thyroid hormones, insulin-like growth factor-1 (IGF-1) and IGF- binding proteins (IGFBPs) levels, in children who has palpable goiter at endemic population. We aimed to 1) compare children with palpable goiter with healthy peers, 2) detect interaction of anthropometric indices, serum thyroid hormones, IGF-1 and IGFBPs parameters in both groups 3) evaluate the effects of their nutritional status to these parameters. Subjects and Methods: We performed goiter palpation to 1018 child and found goiter at 81 child. Seventy-three pubertal children were included in this study. Seventy-five healthy children were defined as the control group. Weight and height of all children were measured. Thyroid hormone levels, IGF-1, IGFBP-3, and IGFBP-1 were assessed in both groups. Results: Height and weight SDS were significantly lower in children who had goiter by palpation than healthy peers (p<0.05). Free T4 (FT4) levels were significantly higher in control group than children with palpable goiter (p<0.05). IGF-1 level and IGF-1 SDS were significantly lower in children with palpable goiter (p<0.001), IGFBP3 and IGFBP1 levels were not significantly different between the two groups (p>0.05). Serum IGF-1 and IGFBP-3 levels were significantly lower (p<0.05) in underweight children with goiter than normal weight group. In the presence of goiter, IGF-1 levels were lower (B: 0.97, 95% CI: 0.960.98, p<0.001). Conclusion: In endemic areas, children with palpable goiter were shorter and thinner than the healthy peers. Thyroid hormones were between the reference ranges. In children with palpable goiter, IGF-1 levels were lower and IGFBP-3 and IGFBP-1 levels were not different from the healthy control group. However, at the presence of goiter IGF-1 levels decrease. This decrease can be the result of insufficient nutrition and result in short stature and weakness than their healthy peers. © Georg Thieme Verlag KG Stuttgart, New York.Item Current practice in diagnosis and treatment of growth hormone deficiency in childhood: A survey from Turkey(Galenos Yayincilik,, 2015) Poyrazoğlu Ş.; Akçay T.; Arslanoğlu I.; Atabek M.E.; Atay Z.; Berberoğlu M.; Bereket A.; Bideci A.; Bircan I.; Böber E.; Can Ş.; Cesur Y.; Darcan Ş.; Demir K.; Dündar B.; Ersoy B.; Esen I.; Güven A.; Kara C.; Keskin M.; Kurtoğlu S.; Memioğlu N.; Özbek M.N.; Özgen T.; Sari E.; Şiklar Z.; Şimşek E.; Turan S.; Yeşilkaya E.; Yuksel B.; Darendeliler F.Objective: Approaches to diagnosis and treatment of growth hormone deficiency (GHD) in children vary among countries and even among centers in the same country. This survey, aiming to facilitate the process of preparing the new consensus on GHD by the Turkish Pediatric Endocrinology and Diabetes Society, was designed to evaluate the current practices in diagnosis and treatment of GHD in different centers in Turkey. Methods: A questionnaire covering relevant items for diagnosis and treatment of GHD was sent out to all pediatric endocrinology centers. Results: Twenty-four centers returned the questionnaire. The most frequently used GH stimulation test was L-dopa, followed by clonidine. Eighteen centers used a GH cut-off value of 10 ng/mL for the diagnosis of GHD; this value was 7 ng/mL in 4 centers and 5 ng/mL in 2 centers. The most frequently used assay was immunochemiluminescence for determination of GH, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 concentrations. Sex steroid priming in both sexes was used by 19 centers. The most frequently used starting dose of recombinant human GH (rhGH) in prepubertal children was 0.025-0.030 mg/kg/day and 0.030-0.035 mg/kg/day in pubertal children. Growth velocity was used in the evaluation for growth response to rhGH therapy in all centers. Anthropometric measurements of patients every 3-6 months, fasting blood glucose, bone age and thyroid panel evaluation were used by all centers at follow-up. Main indications for cessation of therapy were decreased height velocity and advanced bone age. Fourteen centers used combined treatment (rhGH and gonadotropin-releasing analogues) to increase final height. Conclusion: Although conformity was found among centers in Turkey in current practice, it is very important to update guideline statements and to modify, if needed, the approach to GHD over time in accordance with new evidence-based clinical studies. © Journal of Clinical Research in Pediatric Endocrinology.